Speciality: Cardiology
Description:
A warm welcome to all the medical professionals in this interesting session on understanding the management of ATTRCM with the use of Vyndamax.
ATTR-CM is a protein deposition disorder that affects the heart, leading to structural damage and heart failure. It can be classified as wild type ATTR-CM or hereditary ATTR-CM.
Diagnostic tools like scintigraphy and hematologic tests are essential for confirming the diagnosis of ATTR-CM. Scintigraphy helps visualize the extent of amyloid deposition, while hematologic tests detect monoclonal proteins.
Vyndamax, a drug by Pfizer, has shown promising results in the treatment of ATTR-CM. It stabilizes the protein and prevents further amyloid deposition, improving patient outcomes and reducing mortality.
Therefore, get an overall knowledge regarding understanding the importance of Tafamidis drug in controlling ATTRCM. Listen to the webinar, grab the knowledge that is shared, and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Chemo-Free Regimen for Ph+ ALL Yields High Rate of Deep MRD Negativity
2.
Novel Treatment Shows Promise for Oral Mucositis Caused by Radiation.
3.
Cancer diagnosis does not spur improvements to survivors' diets or eating habits
4.
Innovative oncology therapeutics are being created in collaboration between Moderna and Immatics.
5.
Microplastics can cause malignant changes in lung cells
1.
Exploring the Potential of Cytologic Atypia in Cancer Diagnosis
2.
Personalized Cancer Vaccines: The Next Frontier in Precision Oncology
3.
AI-Powered Rehabilitation: A Game Changer for Hemophilia Management
4.
Targeting the Tumor Microenvironment: Next-Generation Strategies for Immuno-Oncology Success
5.
Unlocking the Benefits of Cyramza: A New Frontier in Cancer Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
2.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
3.
Current Scenario of Cancer- The Incidence of Cancer in Men
4.
Navigating the Complexities of Ph Negative ALL - Part I
5.
From Relapse to Remission : Chasing the Invisible and Redefining Long-Term Survival in Adult R/R B-Cell ALL
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation